Managing hematological malignancies in the COVID-19 era: 12 months on, what have we learned?
9 February 2021

Managing hematological malignancies in the COVID-19 era: 12 months on, what have we learned?

Join our expert faculty for this series of live, interactive broadcasts, each focussed on a specific topic relevant to hematologists treating patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin’s lymphoma (NHL).

Pre-register for your chance to submit questions to our expert faculty in advance of each broadcast. During each live broadcast you will also be able ...

more info...

EM-49343
What's new in the ESMO guidelines?
11 February 2021

What's new in the ESMO guidelines?

Learning objective:

After participating in this broadcast you should be able to:

  • Explain the latest updates to the ESMO guidelines for managing patients with multiple myeloma  

 

Moderator:

  • Mohamad Mohty (France)

 

Faculty:

  • Philippe Moreau (France)
more info...

EM-48507
Challenging cases in mantle cell lymphoma
23 February 2021

Challenging cases in mantle cell lymphoma

Join our expert faculty for this series of live, interactive broadcasts, each focussed on a specific topic relevant to hematologists treating patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin’s lymphoma (NHL).

Pre-register for your chance to submit questions to our expert faculty in advance of each broadcast. During each live broadcast you will also be able ...

more info...

EM-49344
The key things you need to know about managing cardiac morbidities in patients with CLL
9 March 2021

The key things you need to know about managing cardiac morbidities in patients with CLL

Join our expert faculty for this series of live, interactive broadcasts, each focussed on a specific topic relevant to hematologists treating patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin’s lymphoma (NHL).

Pre-register for your chance to submit questions to our expert faculty in advance of each broadcast. During each live broadcast you will also be able ...

more info...

EM-49345
High risk myeloma - what does it mean and how to treat it?
11 March 2021

High risk myeloma - what does it mean and how to treat it?

Learning objective:

After participating in this broadcast you should be able to:

  • Explain the definition of high-risk multiple myeloma and treatment options for patients  

 

Moderator:

  • Mohamad Mohty (France)

 

Faculty:

  • María Victoria Mateos (Spain)
more info...

EM-48508
Challenging cases in Waldenström’s macroglobulinemia
23 March 2021

Challenging cases in Waldenström’s macroglobulinemia

Join our expert faculty for this series of live, interactive broadcasts, each focussed on a specific topic relevant to hematologists treating patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin’s lymphoma (NHL).

Pre-register for your chance to submit questions to our expert faculty in advance of each broadcast. During each live broadcast you will also be able ...

more info...

EM-49346
Minimal Residual Disease - the end of the rainbow?
8 April 2021

Minimal Residual Disease - the end of the rainbow?

Learning objective:

After participating in this broadcast you should be able to:

  • Explain the role of minimal residual disease in the management of patients with multiple myeloma    

 

Moderator:

  • Mohamad Mohty (France)

 

Faculty:

  • Michel Delforge (Belgium)
  • Jesús San Miguel (Spain)
more info...

EM-48509
Using genomics to guide clinical management in CLL
13 April 2021

Using genomics to guide clinical management in CLL

Join our expert faculty for this series of live, interactive broadcasts, each focussed on a specific topic relevant to hematologists treating patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin’s lymphoma (NHL).

Pre-register for your chance to submit questions to our expert faculty in advance of each broadcast. During each live broadcast you will also be able ...

more info...

EM-49347
Where are we with MRD assessment in CLL management?
27 April 2021

Where are we with MRD assessment in CLL management?

Join our expert faculty for this series of live, interactive broadcasts, each focussed on a specific topic relevant to hematologists treating patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin’s lymphoma (NHL).

Pre-register for your chance to submit questions to our expert faculty in advance of each broadcast. During each live broadcast you will also be able ...

more info...

EM-49349
AL Amyloidosis management in 2021: more progress than ever
4 May 2021

AL Amyloidosis management in 2021: more progress than ever

Learning objective:

After participating in this broadcast you should be able to:

  • Describe new developments in the management of patients with AL amyloidosis    

 

Moderator:

  • Michel Delforge (Belgium)

 

Faculty:

  • Giovanni Palladini (Italy)
more info...

EM-48510